Disease · MONDO_0018922
cold agglutinin disease
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. cold agglutinin disease. Diseases, record MONDO_0018922. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0018922
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs11
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| SUTIMLIMAB | CHEMBL4297832 | Antibody | Approval | PMDA | 6 | 5 | 5 | Drugs and targets |
| ANTITHROMBIN GAMMA | CHEMBL4594458 | Approval | PMDA | 1 | 0 | 0 | Drugs and targets | |
| PEGCETACOPLAN | CHEMBL4298211 | Protein | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| RITUXIMAB | CHEMBL1201576 | Antibody | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| BENDAMUSTINE | CHEMBL487253 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| BORTEZOMIB | CHEMBL325041 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ECULIZUMAB | CHEMBL1201828 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| FLUDARABINE | CHEMBL1568 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ZANUBRUTINIB | CHEMBL3936761 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| POVETACICEPT | CHEMBL5095306 | Protein | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 11
See all 11 drugsTargets43
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| ADRM1 | 26S proteasome | 1 | 26S proteasome inhibitor | Phase 2 | https://conductscience.org/library/genes/11047 | Drugs and targets |
| BTK | Tyrosine-protein kinase BTK | 1 | Tyrosine-protein kinase BTK inhibitor | Phase 2 | https://conductscience.org/library/genes/695 | Drugs and targets |
| C1S | Complement C1s subcomponent | 1 | Complement C1s inhibitor | Approval | https://conductscience.org/library/genes/716 | Drugs and targets |
| C3 | Complement C3 | 1 | Complement C3 inhibitor | Phase 3 | https://conductscience.org/library/genes/718 | Drugs and targets |
| C5 | Complement C5 | 1 | Complement C5 inhibitor | Phase 2 | https://conductscience.org/library/genes/727 | Drugs and targets |
| MS4A1 | B-lymphocyte antigen CD20 | 1 | B-lymphocyte antigen CD20 binding agent | Phase 2 | https://conductscience.org/library/genes/931 | Drugs and targets |
| PSMA1 | 26S proteasome | 1 | 26S proteasome inhibitor | Phase 2 | https://conductscience.org/library/genes/5682 | Drugs and targets |
| PSMA2 | 26S proteasome | 1 | 26S proteasome inhibitor | Phase 2 | https://conductscience.org/library/genes/5683 | Drugs and targets |
| PSMA3 | 26S proteasome | 1 | 26S proteasome inhibitor | Phase 2 | https://conductscience.org/library/genes/5684 | Drugs and targets |
| PSMA4 | 26S proteasome | 1 | 26S proteasome inhibitor | Phase 2 | https://conductscience.org/library/genes/5685 | Drugs and targets |
1 to 10 of 43
See all 43 targetsTrials15
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03347422 | A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Without A Recent History of Blood Transfusion | Phase 3 | 42 | 2022-12-23 | Cold Agglutinin Disease | SUTIMLIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03226678 | Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD) | Phase 2 | 24 | 2024-12-12 | Warm Autoimmune Hemolytic Anemia, Cold Agglutinin Disease | PEGCETACOPLAN | Its record names the disease | ClinicalTrials.gov |
| NCT03347396 | A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion (Cardinal Study) | Phase 3 | 24 | 2022-10-31 | Agglutinin Disease, Cold | SUTIMLIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT05096403 | A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Cold Agglutinin Disease (CAD) | Phase 3 | 24 | 2025-10-30 | Cold Agglutinin Disease | PEGCETACOPLAN | Its record names the disease | ClinicalTrials.gov |
| NCT05132127 | Sutimlimab (BIVV009) for the Adult Participants With Cold Agglutinin Disease (CAD) Who Have Completed Phase 3 Studies (CARDINAL or CADENZA) in Japan | Phase 3 | 7 | 2023-10-03 | Cold Agglutinin Disease | SUTIMLIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT05791708 | Cold Agglutinin Disease Real World Evidence Registry | 429 | Cold Agglutinin Disease (CAD), Cold Agglutinin Syndrome (CAS) | SUTIMLIMAB | Its record names the disease | ClinicalTrials.gov | ||
| NCT02502903 | Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement Mediated Disorders | Phase 1 | 122 | Bullous Pemphigoid (BP), Cold Agglutinin Disease (CAD), Warm Autoimmune Hemolytic Anemia (WAIHA), End-stage Renal Disease (ESRD) | SUTIMLIMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT02689986 | Bendamustine and Rituximab Combination Therapy for Cold Agglutinin Disease | Phase 2 | 43 | Cold Agglutinin Disease, Autoimmune Hemolytic Anemia | BENDAMUSTINE, RITUXIMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT00373594 | Therapy for Chronic Cold Agglutinin Disease | Phase 2 | 30 | Cold Agglutinin Disease | FLUDARABINE, RITUXIMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT05757570 | An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias (RUBY-4) | Phase 1/2 | 30 | Idiopathic Thrombocytopenic Purpura, Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia, Cold Agglutinin Disease | POVETACICEPT | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 15
See all 15 trialsComparisons in its trials11
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Pegcetacoplan Double Blind During Part A vs Placebo Matching Pegcetacoplan-Double-blind During Part A: Number of Patients Achieving Transfusion Avoidance From Week 5 to Week 24-Part A | 12 of 16 | 5 of 8 | 24 | NCT05096403 | Trial comparisons |
| Pegcetacoplan Double Blind During Part A vs Placebo Matching Pegcetacoplan-Double-blind During Part A: Number of Patients Achieving a Response (R) at Week 24 | 8 of 16 | 2 of 8 | 24 | NCT05096403 | Trial comparisons |
Pegcetacoplan Double Blind During Part A vs Placebo Matching Pegcetacoplan-Double-blind During Part A: Count and Percentage of Patients With a First Normalization From Baseline by Week 24 for Hemoglobin Levels-Part A | 7 of 16 | 0 of 8 | 24 | NCT05096403 | Trial comparisons |
| Pegcetacoplan Double Blind During Part A vs Placebo Matching Pegcetacoplan-Double-blind During Part A: Normalization of Markers of Hemolysis (LDH) at Week 24-Part A | 5 of 13 | 1 of 8 | 21 | NCT05096403 | Trial comparisons |
Pegcetacoplan Double Blind During Part A vs Placebo Matching Pegcetacoplan-Double-blind During Part A: Count and Percentage of Patients With a First Normalization From Baseline by Week 24 for LDH Levels-Part A | 6 of 13 | 2 of 8 | 21 | NCT05096403 | Trial comparisons |
| Pegcetacoplan Double Blind During Part A vs Placebo Matching Pegcetacoplan-Double-blind During Part A: Normalization of Markers of Hemolysis (Haptoglobin) at Week 24-Part A | 4 of 15 | 0 of 6 | 21 | NCT05096403 | Trial comparisons |
Pegcetacoplan Double Blind During Part A vs Placebo Matching Pegcetacoplan-Double-blind During Part A: Count and Percentage of Patients With a First Normalization From Baseline by Week 24 for Haptoglobin Levels-Part A | 7 of 15 | 0 of 6 | 21 | NCT05096403 | Trial comparisons |
Pegcetacoplan Double Blind During Part A vs Placebo Matching Pegcetacoplan-Double-blind During Part A: Count and Percentage of Patients With a First Normalization From Baseline by Week 24 for Indirect Bilirubin Levels-Part A | 11 of 13 | 1 of 6 | 19 | NCT05096403 | Trial comparisons |
| Pegcetacoplan Double Blind During Part A vs Placebo Matching Pegcetacoplan-Double-blind During Part A: Normalization of Markers of Hemolysis (Indirect Bilirubin) at Week 24-Part A | 9 of 13 | 1 of 6 | 19 | NCT05096403 | Trial comparisons |
Pegcetacoplan Double Blind During Part A vs Placebo Matching Pegcetacoplan-Double-blind During Part A: Count and Percentage of Patients With a First Normalization From Baseline by Week 24 for ARC Levels-Part A | 9 of 10 | 3 of 8 | 18 | NCT05096403 | Trial comparisons |
1 to 10 of 11
See all 11 comparisons in its trialsPapers from its trials18
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it | Source |
|---|---|---|---|
| 40308078 | DERIVED | 2 | PubMed |
| 39486046 | DERIVED | 1 | PubMed |
| 38995690 | DERIVED | 1 | PubMed |
| 38085846 | DERIVED | 1 | PubMed |
| 37459203 | DERIVED | 1 | PubMed |
| 37246953 | DERIVED | 1 | PubMed |
| 36403132 | DERIVED | 1 | PubMed |
| 35999387 | DERIVED | 1 | PubMed |
| 35687757 | DERIVED | 1 | PubMed |
| 34778998 | DERIVED | 1 | PubMed |
1 to 10 of 18
See all 18 papers from its trialsData dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0018922
GET https://conductscience.org/api/diseases/v1/MONDO_0018922/targets?page=2